Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

PROCEPT BioRobotics Corp PRCT

Healthcare Medical Devices
PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.


NDAQ:PRCT - Post by User

PROCEPT BioRobotics Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(231)
•••
Post by whytestockson May 01, 2024 2:45pm
41 Views
Post# 36017904

PROCEPT BioRobotics Reports First Quarter 2024 Financial Res

PROCEPT BioRobotics Reports First Quarter 2024 Financial Res
JUST IN: $PRCT PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceSAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics &#xAE; Corporation (Nasdaq: PRCT) (the &#x201C;Company&#x201D;), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results f...PRCT - PROCEPT BioRobotics Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities